Literature DB >> 24140076

Adherence to blood pressure-lowering drugs and resistant hypertension: should trial of direct observation therapy be part of preassessment for renal denervation?

Marcel Ruzicka1, Brendan McCormick, Frans H H Leenen, Michael Froeschl, Swapnil Hiremath.   

Abstract

Renal denervation (RDN) is increasingly used for resistant hypertension. We report here a case of pseudoresistance of hypertension caused by nonadherence to prescribed drug therapy (6 medications), which evaded detection by verification of prescription filling. Direct observation therapy (DOT), in which usual antihypertensive medications are given under supervision, produced substantial reductions in blood pressure, which was subsequently controlled chronically with 3 antihypertensive agents, confirming pseudoresistant hypertension. The novel teaching points are that evaluation of nonadherence to drug therapy is a crucial component in diagnosing resistant hypertension before RDN and that DOT may be extremely useful in avoiding an unnecessary and costly procedure.
Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24140076     DOI: 10.1016/j.cjca.2013.07.678

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  3 in total

Review 1.  Can drugs work in patients who do not take them? The problem of non-adherence in resistant hypertension.

Authors:  Marcel Ruzicka; Swapnil Hiremath
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

Review 2.  Medication adherence and resistant hypertension.

Authors:  D J Hyman; V Pavlik
Journal:  J Hum Hypertens       Date:  2014-09-11       Impact factor: 3.012

3.  The Prevalence of Nonadherence in Patients With Resistant Hypertension: A Systematic Review Protocol.

Authors:  Gabrielle Bourque; Julius Vladimir Ilin; Marcel Ruzicka; Alexandra Sascha Davis; Swapnil Hiremath
Journal:  Can J Kidney Health Dis       Date:  2019-12-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.